Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Antiviral Drugs - APAC

APAC
  • Revenue in the Antiviral Drugs market is projected to reach US$9.17bn in 2024.
  • Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 0.37%, resulting in a market volume of US$9.31bn by 2028.
  • In global comparison, most revenue will be generated United States (US$30.64bn in 2024).

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

In-Scope

  • HIV
  • Hepatitis B and hepatitis C
  • Ebola
  • COVID-19

Out-Of-Scope

  • Vaccines
  • Antibiotics
  • Immunosuppressants
  • In vitro diagnostics and rapid tests
Pharmaceuticals

Pharmaceuticals

Related markets:
Antiviral Drugs: market data & analysis - Cover

Market Insights report

Antiviral Drugs: market data & analysis

Study Details
    methodology

    Download PDF

    FAQs and more info on the methodology

    Revenue

    Notes: Data was converted from local currencies using average exchange rates of the respective year.

    Most recent update: Mar 2024

    Source: Statista Market Insights

    Analyst Opinion

    The Antiviral Drugs market is expected to experience significant growth, which is mainly driven by the testing of novel treatments for COVID-19. There are also more general drivers of the market: the rising number of HIV cases worldwide and the need for continuous development in the field of antiviral drugs as it is in the nature of viruses to mutate and thus to increase their tolerance to drugs. Growing revenues generated by drugs with active patents and the counteracting decline in the case of other drugs which face competition result in stagnant growth.

    The largest area in this market is HIV. In parts of the world, antiviral drugs have succeeded in keeping HIV a chronic condition without its progressing to AIDS. For hepatitis C, the number of new patients is shrinking in the U.S. and in Europe. Due to the COVID-19 pandemic, fewer new patients decided to seek medical treatment, leading to a certain decline in the revenue of HIV drugs.

    Clinical testing and emergency approvals of treatments for COVID-19 have led to an increase in revenue. After a considerable growth in 2022, the revenues are expected to remain at a high level.

    Global Comparison

    Most recent update: Mar 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Antiviral Drugs: market data & analysis - BackgroundAntiviral Drugs: market data & analysis - Cover

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.
    More data on the topic
    Revenue of the worldwide pharmaceutical market in 2023
    1.6tr USD
    Revenue share of the North American pharmaceutical market in 2023
    53.3%
    Pharmaceutical sales in oncologics in 2023
    214bn USD

    Contact

    Get in touch with us. We are happy to help.